Linagliptin CAS 668270-12-0 Purity ≥99.0% (HPLC) Factory

Short Description:

Chemical Name: Linagliptin

CAS: 668270-12-0

Purity: ≥99.0% (HPLC)

Appearance: White or Off-White Crystalline Powder

Linagliptin for the treatment of type II diabetes mellitus

API, High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Manufacturer Supply, High Purity, Commercial Production
Chemical Name: Linagliptin
CAS: 668270-12-0

Chemical Properties:

Chemical Name	Linagliptin
Synonyms	BI-1356; 8-[(3R)-3-Amino-1-piperidinyl]-7-(2-butynyl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione
CAS Number	668270-12-0
CAT Number	RF-API105
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C25H28N8O2
Molecular Weight	472.54
Melting Point	197.0 to 200.0℃
Solubility	Soluble in DMSO
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White or Off-White Crystalline Powder
NMR	Consistent With Structure
Purity / Analysis Method	≥99.0% (HPLC)
Loss on Drying	≤0.50%
Residue on Ignition	≤0.10%
Heavy Metals	≤10ppm
Related Substances
Single Impurity	≤0.50%
Total Impurities	≤1.0%
Isomer	≤0.15%
Residual Solvents
Methanol	≤3000ppm
Isopropanol	≤5000ppm
DMF	≤800ppm
Dichloromethane	≤600ppm
Test Standard	Enterprise Standard
Usage	API

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.

Advantages:

FAQ:

Application:

Linagliptin (CAS: 668270-12-0) is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes. Two pharmacological characteristics that sets linagliptin apart from other DPP-4 inhibitors is that it has a non-linear pharmacokinetic profile and is not primarily eliminated by the renal system. Linagliptin (once-daily) was approved by the US FDA on 2 May 2011 for treatment of type II diabetes. It is being marketed by Boehringer Ingelheim and Lilly. Linagliptin, sold under the brand name Tradjenta among others. It is used together with exercise and diet.